MCM2 was reported to be expressed more frequently than the published marker Ki-67, indicating that it could be a promising independent prognostic marker in breast cancer (Gonzalez et al., 2003; Issac et al., 2019). This evidence concerns the gene MCM2 and breast carcinoma.